Citations 13
Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Chanan‐Khan, Asher , Agarwal, Amit , Kumar, Shaji , Diehl, Susan, Cordero, Jaclyn, Munasinghe, Wijith, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Moreau, Philippe , Roberts, Andrew W. , Facon, Thierry T.F. , Touzeau, Cyrille , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Moreau, Philippe , Chanan‐Khan, Asher , Roberts, Andrew W. , Agarwal, Amit B., Kumar, Shaji , Touzeau, Cyrille , Punnoose, Elizabeth A. , Cordero, Jaclyn, Munasinghe, Wijith, Jia, Jia , Salem, Ahmed Hamed , Freise, Kevin J. , Enschede, Sari H., Maciag, Paulo , Verdugo, Maria, Roberts, Andrew W , Moreau, Philippe , Touzeau, Cyrille , Facon, Thierry T.F. , Leverson, Joel D. , Ross, Jeremy A. , Harrison, Simon J , Salem, Ahmed Hamed
Blood | August 29, 2017 | Volume: 130 | Issue: 22 | Pages: 2392-2400
Key Points In relapsed/refractory MM, venetoclax plus bortezomib and dexamethasone appears to be safe and efficacious. This is a novel therapeutic approach for MM.
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Komrokji, Rami S. , Seymour, John F. , Roberts, Andrew W. , Wadleigh, Martha , To, Luen Bik, Scherber, Robyn M. , Turba, E , Dorr, Andrew, Zhu, Joy, Wang, Lixia , Granston, Tanya, Campbell, Mary S., Scherber, Robyn, Mesa, Ruben A. , Roberts, Andrew W , Komrokji, Rami S
Blood | March 11, 2015 | Volume: 125 | Issue: 17 | Pages: 2649-2655
Key Points Pacritinib reduced myelofibrosis-related splenomegaly and patient symptoms without causing clinically significant myelosuppression. Pacritinib had activity and was well tolerated in patients with preexisting anemia and thrombocytopenia.